Vor Biopharma Inc. (NASDAQ:VOR) Receives $68.43 Average PT from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR) has earned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $68.4286.

A number of research firms have recently commented on VOR. Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Robert W. Baird upgraded Vor Biopharma from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $20.00 to $64.00 in a research report on Wednesday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Wednesday, September 24th. Finally, Zacks Research raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th.

Vor Biopharma Trading Down 6.8%

Shares of VOR opened at $13.72 on Friday. The company’s 50 day moving average price is $14.57. Vor Biopharma has a one year low of $2.62 and a one year high of $65.80. The firm has a market capitalization of $142.83 million, a P/E ratio of -0.04 and a beta of 2.08.

Insiders Place Their Bets

In related news, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the business’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $30.05, for a total transaction of $349,060.80. Following the sale, the insider owned 1,167,109 shares in the company, valued at $35,071,625.45. The trade was a 0.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. sold 24,579 shares of the company’s stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $25.12, for a total value of $617,424.48. Following the completion of the transaction, the director directly owned 779,652 shares of the company’s stock, valued at approximately $19,584,858.24. The trade was a 3.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 1,674,800 shares of company stock worth $49,516,960. Insiders own 0.45% of the company’s stock.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its holdings in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the last quarter. XTX Topco Ltd acquired a new stake in Vor Biopharma during the 2nd quarter worth approximately $66,000. OMERS ADMINISTRATION Corp bought a new stake in Vor Biopharma during the 1st quarter worth approximately $100,000. Jane Street Group LLC bought a new stake in Vor Biopharma during the 1st quarter worth approximately $140,000. Finally, Squarepoint Ops LLC acquired a new position in Vor Biopharma in the 3rd quarter valued at approximately $230,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).